

# Appendix 4E

## Preliminary final report Year ending on 30 June 2012

### 1. Reporting period

The financial information contained in this report is for the year ended 30 June 2012. Comparative amounts are for the year ended 30 June 2011.

### 2. Results for announcement to the market

		Current year reported amount \$	Change up/(down) from previous year \$	Change up/(down) from previous year %
2.1	Revenue from ordinary activities	38,279,902	(82,598,380)	(68.3%)
2.2	Loss from ordinary activities after tax attributable to members	71,145,314	161,751,904	178.5%
2.3	Net loss for the year attributable to members.	71,145,314	161,751,904	178.5%
2.4	No dividends are being proposed or have been paid	Nil	Nil	Nil

### 3. Commentary related to the above results

- Revenue from ordinary activities includes revenue from continuing operations of \$38.2m and other income of \$0.1m. Revenue from continuing operations includes commercialisation revenue of \$27.7m (2011: \$14.6m) and interest revenue of \$10.5m (2011: \$4.7m). Included in other income is Government grant revenue of \$0.1m (2011:nil). Other income for the prior year included one-off items, being a gain on revaluation of investment to fair value of \$86.7m and share of losses of equity accounted associates written back on acquisition of \$14.9m.
- Loss from ordinary activities after tax attributable to members is largely made up of the revenue and other income items discussed above, after expenditure incurred for the development and commercialisation of the platform technology. Further information on expenses from continuing operations can be found in note 2 in the accompanying financial report.
- Net loss for the year attributable to members includes a tax expense for the year of \$22.4m relating to taxable income from operations incurred in Mesoblast Inc. There is no resulting tax charge in the parent company which remains in a tax loss position.

+ See chapter 19 for defined terms.

**4. Net tangible asset (NTA) backing per share**

	<b>Current year</b>	<b>Previous corresponding period</b>
NTA backing per share	40.07 cents	60.05 cents

**5. Other documents accompanying this Appendix 4E**

A copy of the audited financial report and directors' report for the year ending 30 June 2012 for the Mesoblast Group is attached and should be read in conjunction with this Appendix 4E.

**6. Audited Annual Report 2012**

This report has been based on accounts which have been audited. A copy of the audited financial report and directors' report for the year ended 30 June 2012 is attached to this report.

---

<sup>+</sup> See chapter 19 for defined terms.